Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases.

We found that treatment with PEDD of nelitolimod as monotherapy reduced MDSCs within TME (trending towards significance mean % of MDSCs±SEM—nelitolimod 15.7±2.8 vs Veh 25.9±4.5; p=0.07) compared with Veh, further significantly augmented by Sys or SQ α-PD-1 ( figure 2A , mean % of MDSCs±SEM – SQ/Sys – 8.3±1.4/10.9±2.4 vs Veh 25.9±4.5; p<0.01).

also in 128 other papers